Home > Neurology > EAN 2020 > Headache and Pain > Effects of galcanezumab on health-related quality of life

Effects of galcanezumab on health-related quality of life

Presented by
Dr Stewart Tepper, Geisel School of Medicine, USA
EAN 2020
Phase 3, CONQUER
Patients with treatment-resistant episodic or chronic migraine treated with the calcitonin gene-related peptide inhibitor galcanezumab reported better daily functioning and patient perception of health state, compared with placebo, as well as less disability. This was concluded from results of the CONQUER study [1].

Treatment resistance was defined as previous failure with 2 to 4 standard-of-care migraine preventive medication categories in the past 10 years due to inadequate efficacy and/or safety/tolerability issues. Participants were randomised to galcanezumab 120 mg/month (240 mg loading dose) or placebo for 3 months. Migraine Disability Assessment (MIDAS), European Quality of Life 5-Dimensions 5-Levels (EQ-5D-5L), and Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) scores were collected at baseline and month 3; MSQ as well at month 1 and 2.

In the intent-to treat (ITT) population (n=462), mean improvement with galcanezumab versus placebo on EQ-5D-5L visual analog scale was significant (P=0.03). In the ITT and subpopulations with episodic (n=269) and chronic migraine (n=193), mean improvements from baseline in MSQ total and all domain scores were significantly greater with galcanezumab versus placebo (all P<0.0001), as well as improvements in MIDAS total scores (see Table).

Table. Mean change in health-related QoL measures [1]

*P<0.05, **P<0.01, ***P<0.0001 vs placebo. LS, least squares; ITT, intention-to-treat; EM, episodic migraine; CM, chronic migraine; MSQ, Migraine-specific quality of life questionnaire v2.1; MIDAS, Migraine disability assessment; EQ-5D-5L, European quality of life 5-dimensions 5-levels; VAS, visual analog scale.

  1. Tepper SJ, et al. Abstract EPR3051, EAN 2020.


Posted on